Stealth BioTherapeutics Corp - ADR

-0.02 (-6.93%)

Stealth BioTherapeutics Presents New Data On ALS Disase Treatment At Symposium

Published: 06/08/2022 11:35 GMT
Stealth BioTherapeutics Corp - ADR (MITO) - Stealth Biotherapeutics Presents New Sbt-272 Data Demonstrating Improvement in Upper Motor Neuron Function in Als Disease Model at Keystone Neurodegeneration Symposium.
Stealth Biotherapeutics Corp- Sbt-272 Improved Neuronal Health, Superior to Other Approved and Investigational Agents.
Stealth Biotherapeutics Corp- Phase 1 Study to Evaluate Safety and Tolerability of Sbt-272 in Healthy Volunteers is Underway.